Physician profile
Mary E Vanderlick
NPI 1144285842
$39,505.37
in general payments reported to CMS, 2019-2025
74 companies · $4,871 in 2025
The $4,871 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,183 · 2020: $3,274 · 2021: $6,576 · 2022: $6,951 · 2023: $5,649 · 2024: $7,001 · 2025: $4,871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Consulting Fee: $900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,620.85 |
| Consulting Fee | $900.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,380.72 | 2019-2025 | Botox, Qulipta, Ubrelvy |
| Abbott Laboratories | $2,344.71 | 2019-2025 | Infinity |
| Biogen, INC. | $2,269.12 | 2019-2025 | Vumerity, Tysabri, Plegridy |
| Sk Life Science, INC. | $1,933.45 | 2020-2025 | Xcopri |
| Ucb, INC. | $1,910.51 | 2019-2025 | Rystiggo, Nayzilam, Briviact |
| Teva Pharmaceuticals USA, INC. | $1,853.26 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Biohaven Pharmaceuticals, INC. | $1,775.09 | 2021 | |
| Amgen INC. | $1,752.70 | 2019-2023 | Aimovig |
| Amneal Pharmaceuticals LLC | $1,620.92 | 2019-2025 | Rytary, Crexont, Ongentys |
| Genentech USA, INC. | $1,552.26 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $1,550.41 | 2019-2025 | Ultomiris, Soliris |
| Novartis Pharmaceuticals Corporation | $1,279.88 | 2019-2025 | |
| Allergan, INC. | $1,208.30 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $1,183.54 | 2019-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $1,121.13 | 2019-2025 | Kisunla, Amyvid, Emgality |
Show all 74 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Vanderlick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.